Literature DB >> 21533355

Combined expression of urokinase-type plasminogen activator and proliferating cell nuclear antigen at the deepest invasive portion correlates with colorectal cancer prognosis.

S Tatsuta1, S Tanaka, K Haruma, M Yoshihara, K Sumii, G Kajiyama, F Shimamoto.   

Abstract

To examine the relationship among the expression of urokinase-type plasminogen activator (u-PA), invasive/metastatic potential and prognosis of colorectal cancer (CRC), 58 patients with surgically resected advanced CRC were studied. u-PA expression and proliferating cell nuclear antigen labeling index (PCNA-LI) at the deepest invasive portion were examined immunohistochemically. u-PA expression was detected in 37 (63.8%) of 58 lesions. Lesions with liver metastasis showed a significantly (p < 0.01) higher incidence of u-PA expression than those without liver metastasis. Dukes staging also revealed a significant correlation with u-PA expression. The combination of u-PA expression and elevated PCNA-LI at the deepest invasive portion correlated significantly with prognosis. These results indicate that u-PA expression is an important predictor of CRC development and liver metastasis. Furthermore, combined analysis of u-PA expression and PCNA-LI at the deepest invasive portion is very useful in predicting CRC prognosis.

Entities:  

Year:  1997        PMID: 21533355     DOI: 10.3892/ijo.10.1.125

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  2 in total

1.  Potential Applications of DNA, RNA and Protein Biomarkers in Diagnosis, Therapy and Prognosis for Colorectal Cancer: A Study from Databases to AI-Assisted Verification.

Authors:  Xueli Zhang; Xiao-Feng Sun; Bairong Shen; Hong Zhang
Journal:  Cancers (Basel)       Date:  2019-02-01       Impact factor: 6.639

2.  The prognostic value of proliferating cell nuclear antigen expression in colorectal cancer: A meta-analysis.

Authors:  He Zhou; Tao Huang; Yongfu Xiong; Linglong Peng; Rong Wang; Guang Jun Zhang
Journal:  Medicine (Baltimore)       Date:  2018-12       Impact factor: 1.817

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.